

This Document can be made available
in alternative formats upon request

State of Minnesota
HOUSE OF REPRESENTATIVES
NINETIETH SESSION

H. F. No. 3479

03/08/2018 Authored by Franke
The bill was read for the first time and referred to the Committee on Health and Human Services Reform
03/15/2018 By motion, recalled and re-referred to the Committee on Public Safety and Security Policy and Finance

- 1.1 A bill for an act
- 1.2 relating to public safety; modifying the schedules of controlled substances;
- 1.3 amending Minnesota Statutes 2016, section 152.02, subdivision 5; Minnesota
- 1.4 Statutes 2017 Supplement, section 152.02, subdivision 2.
- 1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
- 1.6 Section 1. Minnesota Statutes 2017 Supplement, section 152.02, subdivision 2, is amended
- 1.7 to read:
- 1.8 Subd. 2. **Schedule I.** (a) Schedule I consists of the substances listed in this subdivision.
- 1.9 (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the
- 1.10 following substances, including their analogs, isomers, esters, ethers, salts, and salts of
- 1.11 isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters, ethers,
- 1.12 and salts is possible:
- 1.13 (1) acetylmethadol;
- 1.14 (2) allylprodine;
- 1.15 (3) alphacetylmethadol (except levo-alphacetylmethadol, also known as levomethadyl
- 1.16 acetate);
- 1.17 (4) alphameprodine;
- 1.18 (5) alphamethadol;
- 1.19 (6) alpha-methylfentanyl benzethidine;
- 1.20 (7) betacetylmethadol;
- 1.21 (8) betameprodine;

- 2.1 (9) betamethadol;
- 2.2 (10) betaprodine;
- 2.3 (11) clonitazene;
- 2.4 (12) dextromoramide;
- 2.5 (13) diampromide;
- 2.6 (14) diethylambutene;
- 2.7 (15) difenoxin;
- 2.8 (16) dimenoxadol;
- 2.9 (17) dimepheptanol;
- 2.10 (18) dimethylambutene;
- 2.11 (19) dioxaphetyl butyrate;
- 2.12 (20) dipipanone;
- 2.13 (21) ethylmethylthiambutene;
- 2.14 (22) etonitazene;
- 2.15 (23) etoxeridine;
- 2.16 (24) furethidine;
- 2.17 (25) hydroxypethidine;
- 2.18 (26) ketobemidone;
- 2.19 (27) levomoramide;
- 2.20 (28) levophenacilmorphan;
- 2.21 (29) 3-methylfentanyl;
- 2.22 (30) acetyl-alpha-methylfentanyl;
- 2.23 (31) alpha-methylthiofentanyl;
- 2.24 (32) benzylfentanyl beta-hydroxyfentanyl;
- 2.25 (33) beta-hydroxy-3-methylfentanyl;
- 2.26 (34) 3-methylthiofentanyl;
- 2.27 (35) thenylfentanyl;

- 3.1 (36) thiofentanyl;
- 3.2 (37) para-fluorofentanyl;
- 3.3 (38) morpheridine;
- 3.4 (39) 1-methyl-4-phenyl-4-propionoxypiperidine;
- 3.5 (40) noracymethadol;
- 3.6 (41) norlevorphanol;
- 3.7 (42) normethadone;
- 3.8 (43) norpipanone;
- 3.9 (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
- 3.10 (45) phenadoxone;
- 3.11 (46) phenampromide;
- 3.12 (47) phenomorphan;
- 3.13 (48) phenoperidine;
- 3.14 (49) piritramide;
- 3.15 (50) proheptazine;
- 3.16 (51) properidine;
- 3.17 (52) propiram;
- 3.18 (53) racemoramide;
- 3.19 (54) tilidine;
- 3.20 (55) trimeperidine;
- 3.21 (56) N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl);
- 3.22 (57)
- 3.23 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide(U47700);
- 3.24 ~~and~~
- 3.25 (58) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide(furanylfentanyl);₂
- 3.26 (59) mitragynine;
- 3.27 (60) 7-hydroxymitragynine; and
- 3.28 (61) 4-(4-bromophenyl)-4-dimethylamino-1-phenethylcyclohexanol (bromadol).

(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers, and salts of isomers, unless specifically excepted or unless listed in another schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

(1) acetorphine;

(2) acetyldihydrocodeine;

(3) benzylmorphine;

(4) codeine methylbromide;

(5) codeine-n-oxide;

(6) cyprenorphine;

(7) desomorphine;

(8) dihydromorphine;

(9) drotebanol;

(10) etorphine;

(11) heroin;

(12) hydromorphenol;

(13) methyl-desorphine;

(14) methyldihydromorphine;

(15) morphine methylbromide;

(16) morphine methylsulfonate;

(17) morphine-n-oxide;

(18) myrophine;

(19) nicocodeine;

(20) nicomorphine;

(21) normorphine;

(22) pholcodine; and

(23) thebacon.

(d) Hallucinogens. Any material, compound, mixture or preparation which contains any quantity of the following substances, their analogs, salts, isomers (whether optical, positional,

5.1 or geometric), and salts of isomers, unless specifically excepted or unless listed in another
5.2 schedule, whenever the existence of the analogs, salts, isomers, and salts of isomers is
5.3 possible:

- 5.4 (1) methylenedioxy amphetamine;
- 5.5 (2) methylenedioxymethamphetamine;
- 5.6 (3) methylenedioxy-N-ethylamphetamine (MDEA);
- 5.7 (4) n-hydroxy-methylenedioxyamphetamine;
- 5.8 (5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
- 5.9 (6) 2,5-dimethoxyamphetamine (2,5-DMA);
- 5.10 (7) 4-methoxyamphetamine;
- 5.11 (8) 5-methoxy-3, 4-methylenedioxyamphetamine;
- 5.12 (9) alpha-ethyltryptamine;
- 5.13 (10) bufotenine;
- 5.14 (11) diethyltryptamine;
- 5.15 (12) dimethyltryptamine;
- 5.16 (13) 3,4,5-trimethoxyamphetamine;
- 5.17 (14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
- 5.18 (15) ibogaine;
- 5.19 (16) lysergic acid diethylamide (LSD);
- 5.20 (17) mescaline;
- 5.21 (18) parahexyl;
- 5.22 (19) N-ethyl-3-piperidyl benzilate;
- 5.23 (20) N-methyl-3-piperidyl benzilate;
- 5.24 (21) psilocybin;
- 5.25 (22) psilocyn;
- 5.26 (23) tenocyclidine (TPCP or TCP);
- 5.27 (24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
- 5.28 (25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);

- 6.1 (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
- 6.2 (27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
- 6.3 (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
- 6.4 (29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
- 6.5 (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
- 6.6 (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
- 6.7 (32) 4-methyl-2,5-dimethoxyphenethylamine (2C-D);
- 6.8 (33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
- 6.9 (34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
- 6.10 (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
- 6.11 (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
- 6.12 (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
- 6.13 (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
- 6.14 (2-CB-FLY);
- 6.15 (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
- 6.16 (40) alpha-methyltryptamine (AMT);
- 6.17 (41) N,N-diisopropyltryptamine (DiPT);
- 6.18 (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
- 6.19 (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
- 6.20 (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
- 6.21 (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
- 6.22 (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
- 6.23 (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
- 6.24 (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
- 6.25 (49) 5-methoxy- α -methyltryptamine (5-MeO-AMT);
- 6.26 (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 6.27 (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);

- 7.1 (52) 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT);
- 7.2 (53) 5-methoxy- α -ethyltryptamine (5-MeO-AET);
- 7.3 (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
- 7.4 (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
- 7.5 (56) 5-methoxy-N,N-diallyltryptamine (5-MeO-DALT);
- 7.6 (57) methoxetamine (MXE);
- 7.7 (58) 5-iodo-2-aminoindane (5-IAI);
- 7.8 (59) 5,6-methylenedioxy-2-aminoindane (MDAI);
- 7.9 (60) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe);
- 7.10 (61) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe);
- 7.11 (62) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe);
- 7.12 (63) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
- 7.13 (64) 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
- 7.14 (65) N,N-Dipropyltryptamine (DPT);
- 7.15 (66) 3-[1-(Piperidin-1-yl)cyclohexyl]phenol (3-HO-PCP);
- 7.16 (67) N-ethyl-1-(3-methoxyphenyl)cyclohexanamine (3-MeO-PCE);
- 7.17 (68) 4-[1-(3-methoxyphenyl)cyclohexyl]morpholine (3-MeO-PCMo);
- 7.18 (69) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine (methoxydine, 4-MeO-PCP);
- 7.19 (70) 2-(2-Chlorophenyl)-2-(ethylamino)cyclohexan-1-one (N-Ethyl-norketamine,
- 7.20 ethketamine, NENK);
- 7.21 (71) methylenedioxy-N,N-dimethylamphetamine (MDDMA);
- 7.22 (72) 3-(2-Ethyl(methyl)aminoethyl)-1H-indol-4-yl (4-AcO-MET); and
- 7.23 (73) 2-Phenyl-2-(methylamino)cyclohexanone (deschloroketamine).
- 7.24 (e) Peyote. All parts of the plant presently classified botanically as *Lophophora williamsii*
- 7.25 Lemaire, whether growing or not, the seeds thereof, any extract from any part of the plant,
- 7.26 and every compound, manufacture, salts, derivative, mixture, or preparation of the plant,
- 7.27 its seeds or extracts. The listing of peyote as a controlled substance in Schedule I does not
- 7.28 apply to the nondrug use of peyote in bona fide religious ceremonies of the American Indian
- 7.29 Church, and members of the American Indian Church are exempt from registration. Any

person who manufactures peyote for or distributes peyote to the American Indian Church, however, is required to obtain federal registration annually and to comply with all other requirements of law.

(f) Central nervous system depressants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

(1) mecloqualone;

(2) methaqualone;

(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;

(4) flunitrazepam; and

(5) 2-(2-Methoxyphenyl)-2-(methylamino)cyclohexanone (2-MeO-2-deschloroketamine, methoxyketamine).

(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation which contains any quantity of the following substances, their analogs, salts, isomers, and salts of isomers whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:

(1) aminorex;

(2) cathinone;

(3) fenethylamine;

(4) methcathinone;

(5) methylaminorex;

(6) N,N-dimethylamphetamine;

(7) N-benzylpiperazine (BZP);

(8) methylmethcathinone (mephedrone);

(9) 3,4-methylenedioxy-N-methylcathinone (methyline);

(10) methoxymethcathinone (methedrone);

(11) methylenedioxypyrovalerone (MDPV);

(12) 3-fluoro-N-methylcathinone (3-FMC);

- 9.1 (13) methylethcathinone (MEC);
- 9.2 (14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
- 9.3 (15) dimethylmethcathinone (DMMC);
- 9.4 (16) fluoroamphetamine;
- 9.5 (17) fluoromethamphetamine;
- 9.6 (18) α -methylaminobutyrophenone (MABP or buphedrone);
- 9.7 (19) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone);
- 9.8 (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
- 9.9 (21) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl) pentan-1-one (naphthylpyrovalerone or
- 9.10 naphyrone);
- 9.11 (22) (alpha-pyrrolidinopentiophenone (alpha-PVP);
- 9.12 (23) (RS)-1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone (4-Me-PHP or MPHP);
- 9.13 (24) 2-(1-pyrrolidinyl)-hexanophenone (Alpha-PHP);
- 9.14 (25) 4-methyl-N-ethylcathinone (4-MEC);
- 9.15 (26) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP);
- 9.16 (27) 2-(methylamino)-1-phenylpentan-1-one (pentedrone);
- 9.17 (28) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentyllone);
- 9.18 (29) 4-fluoro-N-methylcathinone (4-FMC);
- 9.19 (30) 3,4-methylenedioxy-N-ethylcathinone (ethylone);
- 9.20 (31) alpha-pyrrolidinobutiophenone (α -PBP);
- 9.21 (32) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB);
- 9.22 (33) 1-phenyl-2-(1-pyrrolidinyl)-1-heptanone (PV8);
- 9.23 (34) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB);
- 9.24 (35) 4-methyl-alpha-ethylaminopentiophenone (4-MEAPP);
- 9.25 (36) 4'-chloro-alpha-pyrrolidinopropiophenone (4'-chloro-PPP);
- 9.26 (37) 1-(1,3-Benzodioxol-5-yl)-2-(dimethylamino)butan-1-one (dibutylone, bk-DMBDB);
- 9.27 ~~and~~
- 9.28 (38) 1-(3-chlorophenyl) piperazine (meta-chlorophenylpiperazine or mCPP); and

10.1 ~~(38)~~ (39) any other substance, except bupropion or compounds listed under a different
10.2 schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
10.3 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
10.4 compound is further modified in any of the following ways:

10.5 (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
10.6 haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
10.7 system by one or more other univalent substituents;

10.8 (ii) by substitution at the 3-position with an acyclic alkyl substituent;

10.9 (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
10.10 methoxybenzyl groups; or

10.11 (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.

10.12 (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless specifically
10.13 excepted or unless listed in another schedule, any natural or synthetic material, compound,
10.14 mixture, or preparation that contains any quantity of the following substances, their analogs,
10.15 isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence
10.16 of the isomers, esters, ethers, or salts is possible:

10.17 (1) marijuana;

10.18 (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, synthetic
10.19 equivalents of the substances contained in the cannabis plant or in the resinous extractives
10.20 of the plant, or synthetic substances with similar chemical structure and pharmacological
10.21 activity to those substances contained in the plant or resinous extract, including, but not
10.22 limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans tetrahydrocannabinol, and 3,4
10.23 cis or trans tetrahydrocannabinol;

10.24 (3) synthetic cannabinoids, including the following substances:

10.25 (i) Naphthoylindoles, which are any compounds containing a 3-(1-naphthoyl)indole
10.26 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
10.27 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
10.28 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
10.29 extent and whether or not substituted in the naphthyl ring to any extent. Examples of
10.30 naphthoylindoles include, but are not limited to:

10.31 (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);

10.32 (B) 1-Butyl-3-(1-naphthoyl)indole (JWH-073);

11.1 (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);

11.2 (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);

11.3 (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);

11.4 (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);

11.5 (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);

11.6 (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);

11.7 (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);

11.8 (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).

11.9 (ii) Naphthylmethylinroles, which are any compounds containing a

11.10 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the

11.11 indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

11.12 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further

11.13 substituted in the indole ring to any extent and whether or not substituted in the naphthyl

11.14 ring to any extent. Examples of naphthylmethylinroles include, but are not limited to:

11.15 (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);

11.16 (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane (JWH-184).

11.17 (iii) Naphthoylpyrroles, which are any compounds containing a 3-(1-naphthoyl)pyrrole

11.18 structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,

11.19 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or

11.20 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any

11.21 extent, whether or not substituted in the naphthyl ring to any extent. Examples of

11.22 naphthoylpyrroles include, but are not limited to,

11.23 (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).

11.24 (iv) Naphthylmethylindenes, which are any compounds containing a naphthylideneindene

11.25 structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl,

11.26 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or

11.27 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any

11.28 extent, whether or not substituted in the naphthyl ring to any extent. Examples of

11.29 naphthylemethylindenes include, but are not limited to,

11.30 E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).

11.31 (v) Phenylacetylinroles, which are any compounds containing a 3-phenylacetylindole

11.32 structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,

- 12.1 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
12.2 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
12.3 extent, whether or not substituted in the phenyl ring to any extent. Examples of
12.4 phenylacetylindoles include, but are not limited to:
- 12.5 (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
12.6 (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
12.7 (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
12.8 (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
- 12.9 (vi) Cyclohexylphenols, which are compounds containing a
12.10 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic
12.11 ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
12.12 1-(N-methyl-2-piperidiny)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted
12.13 in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, but are not
12.14 limited to:
- 12.15 (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
12.16 (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
12.17 (Cannabicyclohexanol or CP 47,497 C8 homologue);
12.18 (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
12.19 -phenol (CP 55,940).
- 12.20 (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole structure
12.21 with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
12.22 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidiny)methyl or
12.23 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any
12.24 extent and whether or not substituted in the phenyl ring to any extent. Examples of
12.25 benzoylindoles include, but are not limited to:
- 12.26 (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
12.27 (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
12.28 (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (WIN
12.29 48,098 or Pravadoline).
- 12.30 (viii) Others specifically named:

- 13.1 (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 13.2 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
- 13.3 (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
 13.4 -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
- 13.5 (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
 13.6 -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2);
- 13.7 (D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
- 13.8 (E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
 13.9 (XLR-11);
- 13.10 (F) 1-pentyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1H-indazole-3-carboxamide
 13.11 (AKB-48(APINACA));
- 13.12 (G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
 13.13 (5-Fluoro-AKB-48);
- 13.14 (H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22);
- 13.15 (I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro PB-22);
- 13.16 (J) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-3-carboxamide
 13.17 (AB-PINACA);
- 13.18 (K) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-
 13.19 1H-indazole-3-carboxamide (AB-FUBINACA);
- 13.20 (L) N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
 13.21 indazole-3-carboxamide(AB-CHMINACA);
- 13.22 (M) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate
 13.23 (5-fluoro-AMB);
- 13.24 (N) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl) methanone (THJ-2201);
- 13.25 (O) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone
 13.26 (FUBIMINA);
- 13.27 (P) (7-methoxy-1-(2-morpholinoethyl)-N-((1S,2S,4R)-1,3,3-trimethylbicyclo
 13.28 [2.2.1]heptan-2-yl)-1H-indole-3-carboxamide (MN-25 or UR-12);
- 13.29 (Q) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)
 13.30 -1H-indole-3-carboxamide (5-fluoro-ABICA);

- 14.1 (R) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.2 -1H-indole-3-carboxamide;
- 14.3 (S) N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-(5-fluoropentyl)
14.4 -1H-indazole-3-carboxamide;
- 14.5 (T) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido) -3,3-dimethylbutanoate;
- 14.6 (U) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1
14.7 H-indazole-3-carboxamide (MAB-CHMINACA);
- 14.8 (V) N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
14.9 (ADB-PINACA);
- 14.10 (W) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate (FUB-AMB);
- 14.11 (X)
14.12 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide.
14.13 (APP-CHMINACA);
- 14.14 (Y) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FUB-PB-22); and
- 14.15 (Z) methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (MMB-CHMICA).
- 14.16 (i) A controlled substance analog, to the extent that it is implicitly or explicitly intended
14.17 for human consumption.
- 14.18 Sec. 2. Minnesota Statutes 2016, section 152.02, subdivision 5, is amended to read:
- 14.19 Subd. 5. **Schedule IV.** (a) Schedule IV consists of the substances listed in this subdivision.
- 14.20 (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule,
14.21 any material, compound, mixture, or preparation containing any of the following narcotic
14.22 drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities
14.23 as follows:
- 14.24 (1) not more than one milligram of difenoxin and not less than 25 micrograms of atropine
14.25 sulfate per dosage unit;
- 14.26 (2) dextropropoxyphene (Darvon and Darvocet);
- 14.27 (3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and
14.28 geometric isomers, and salts of these isomers (including tramadol); ~~and~~
- 14.29 (4) eluxadoline;₂
- 14.30 (5) pentazocine; and

15.1 (6) butorphanol (including its optical isomers).

15.2 (c) Depressants. Unless specifically excepted or unless listed in another schedule, any
15.3 material, compound, mixture, or preparation containing any quantity of the following
15.4 substances, including its salts, isomers, and salts of isomers whenever the existence of the
15.5 salts, isomers, and salts of isomers is possible:

15.6 (1) alfaxalone (5 α -pregnan-3 α -ol-11,20-dione);

15.7 (2) alprazolam;

15.8 (3) barbital;

15.9 (4) bromazepam;

15.10 (5) camazepam;

15.11 (6) carisoprodol;

15.12 (7) chloral betaine;

15.13 (8) chloral hydrate;

15.14 (9) chlordiazepoxide;

15.15 (10) clobazam;

15.16 (11) clonazepam;

15.17 (12) clorazepate;

15.18 (13) clotiazepam;

15.19 (14) cloxazolam;

15.20 (15) delorazepam;

15.21 (16) diazepam;

15.22 (17) dichloralphenazone;

15.23 (18) estazolam;

15.24 (19) ethchlorvynol;

15.25 (20) ethinamate;

15.26 (21) ethyl loflazepate;

15.27 (22) fludiazepam;

15.28 (23) flurazepam;

- 16.1 (24) fospropofol;
- 16.2 (25) halazepam;
- 16.3 (26) haloxazolam;
- 16.4 (27) ketazolam;
- 16.5 (28) lorazepam;
- 16.6 (29) lorazepam;
- 16.7 (30) lormetazepam mebutamate;
- 16.8 (31) medazepam;
- 16.9 (32) meprobamate;
- 16.10 (33) methohexital;
- 16.11 (34) methylphenobarbital;
- 16.12 (35) midazolam;
- 16.13 (36) nimetazepam;
- 16.14 (37) nitrazepam;
- 16.15 (38) nordiazepam;
- 16.16 (39) oxazepam;
- 16.17 (40) oxazolam;
- 16.18 (41) paraldehyde;
- 16.19 (42) petrichloral;
- 16.20 (43) phenobarbital;
- 16.21 (44) pinazepam;
- 16.22 (45) prazepam;
- 16.23 (46) quazepam;
- 16.24 (47) suvorexant;
- 16.25 (48) temazepam;
- 16.26 (49) tetrazepam;
- 16.27 (50) triazolam;

17.1 (51) zaleplon;

17.2 (52) zolpidem;

17.3 (53) zopiclone.

17.4 (d) Any material, compound, mixture, or preparation which contains any quantity of the
17.5 following substance including its salts, isomers, and salts of such isomers, whenever the
17.6 existence of such salts, isomers, and salts of isomers is possible: fenfluramine.

17.7 (e) Stimulants. Unless specifically excepted or unless listed in another schedule, any
17.8 material, compound, mixture, or preparation which contains any quantity of the following
17.9 substances having a stimulant effect on the central nervous system, including its salts,
17.10 isomers, and salts of isomers:

17.11 (1) cathine (norpseudoephedrine);

17.12 (2) diethylpropion;

17.13 (3) fencamfamine;

17.14 (4) fenproporex;

17.15 (5) mazindol;

17.16 (6) mefenorex;

17.17 (7) modafinil;

17.18 (8) pemoline (including organometallic complexes and chelates thereof);

17.19 (9) phentermine;

17.20 (10) pipradol;

17.21 (11) sibutramine;

17.22 (12) SPA (1-dimethylamino-1,2-diphenylethane).

17.23 (f) lorcaserin.